Cargando…
Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
HIV remains a significant burden, despite expanding HIV prevention tools. Long-acting injectable cabotegravir (CAB-LA) is a new preexposure prophylaxis (PrEP) product. We reviewed existing evidence to determine the efficacy and safety of CAB-LA as PrEP to inform global guidelines. DESIGN: Systematic...
Autores principales: | Fonner, Virginia A., Ridgeway, Kathleen, van der Straten, Ariane, Lorenzetti, Lara, Dinh, Nhi, Rodolph, Michelle, Schaefer, Robin, Schmidt, Heather-Marie A., Nguyen, Van Thi Thuy, Radebe, Mopo, Peralta, Hortencia, Baggaley, Rachel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090368/ https://www.ncbi.nlm.nih.gov/pubmed/36723489 http://dx.doi.org/10.1097/QAD.0000000000003494 |
Ejemplares similares
-
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
por: Fonner, Virginia A., et al.
Publicado: (2016) -
Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
por: Ahluwalia, Amrit Kaur, et al.
Publicado: (2022) -
Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
por: Shaik, Jafar Sadik, et al.
Publicado: (2021) -
Oral preexposure prophylaxis continuation, measurement and reporting
por: Stankevitz, Kayla, et al.
Publicado: (2020) -
Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice
por: Schmidt, Heather‐Marie Ann, et al.
Publicado: (2022)